MDS most often refers to **myelodysplastic syndromes**, a group of bone marrow disorders. In MDS, the bone marrow makes blood cells that are abnormal and do not mature normally. This can lead to low blood counts (cytopenias) such as anemia, low neutrophils, or low platelets. MDS is commonly discussed in hematology-oncology clinics, pathology reports, and cancer-care planning.
Myelodysplastic syndrome is a group of bone marrow disorders that reduce the body’s ability to make healthy blood cells. It is commonly discussed in hematology-oncology clinics because it can cause anemia, infections, and bleeding. It is also used as a diagnostic label and risk category to guide monitoring and treatment planning. In some cases, it can progress to acute myeloid leukemia (AML).
Adult T-cell leukemia/lymphoma is a rare cancer of mature **T lymphocytes** (a type of white blood cell that helps coordinate immune responses). It is most often linked to chronic infection with **HTLV-1 (human T-cell lymphotropic virus type 1)**. The disease can behave like leukemia (cancer cells circulating in the blood and bone marrow), lymphoma (tumors in lymph nodes), or both. The term is commonly used in hematology-oncology to describe a specific diagnosis that guides testing, staging, and treatment planning.
T-cell leukemia is a group of blood cancers that start in T lymphocytes (T cells), a type of white blood cell. It involves abnormal T cells in the blood and bone marrow, and sometimes lymph nodes, liver, spleen, skin, or other organs. The term is commonly used in hematology-oncology to describe specific leukemia subtypes defined by cell markers and genetics. It is also used to guide diagnostic testing, risk assessment, and selection of treatments.
Hairy cell leukemia is a rare, slow-growing blood cancer that starts in B lymphocytes (a type of white blood cell). It is named for the “hairy” appearance of the abnormal cells under a microscope. It most often involves the bone marrow and spleen and can lower normal blood counts. The term is commonly used in hematology-oncology to describe a specific leukemia with characteristic lab and biopsy findings.
CML is short for **chronic myeloid leukemia**, a cancer of the blood and bone marrow. It happens when certain white blood cell–forming cells grow and survive abnormally. CML is commonly discussed in hematology-oncology clinics, pathology reports, and cancer treatment planning. It is typically identified through blood tests and confirmed with specialized genetic testing.
Chronic myeloid leukemia is a blood and bone marrow cancer that affects white blood cell production. It is usually driven by a specific genetic change in leukemia cells that makes them grow and survive too easily. It most often appears in adults and is commonly managed in outpatient hematology-oncology clinics. The term is used in cancer care to describe a distinct leukemia subtype with well-defined diagnostic tests and targeted treatment options.
CLL stands for chronic lymphocytic leukemia. It is a blood and bone marrow cancer that involves abnormal B lymphocytes (a type of white blood cell). CLL is commonly discussed in hematology-oncology clinics, cancer centers, and lab reports. It may be found during routine blood tests or after evaluation of symptoms such as swollen lymph nodes or fatigue.
Chronic lymphocytic leukemia is a blood cancer that starts in certain white blood cells called lymphocytes. It most often involves B lymphocytes, a type of immune cell that normally helps fight infection. It is called “chronic” because it often develops and progresses more slowly than acute leukemias. The term is commonly used in hematology-oncology clinics, cancer centers, and pathology reports to describe this specific leukemia subtype.
AML stands for acute myeloid leukemia, a cancer of the blood and bone marrow. It starts when immature myeloid cells (“blasts”) grow and build up, crowding out normal blood-forming cells. AML is commonly used as a diagnosis in hematology-oncology to explain symptoms like low blood counts and infection risk. It is also used to guide testing, risk classification, and treatment planning.